{"entity":{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","aka":[],"tldr":"IGM Biosciences engineered antibodies of the IgM class, which have ten binding arms instead of two, originally as T-cell engagers for blood cancers and later for autoimmune disease. It ended development and was bought by Concentra Biosciences in 2025.","summary":"IGM Biosciences was a biotechnology company that focused on developing engineered IgM-based therapeutic antibodies, exploiting the ten binding sites of the IgM format for T-cell engagers and other constructs. By mid-2025 the company had wound down development; on 1 July 2025 it agreed to be acquired by Concentra Biosciences for $1.247 per share in cash plus a contingent value right entitling holders to closing net cash above $82 million and 80% of net proceeds from any disposition of product candidates within a year. The tender offer and merger completed on 14 August 2025 and the Nasdaq listing (IGMS) ended. The company's website (igmbio.com) no longer resolves. Its earlier oncology programmes (including CD20xCD3 IgM T-cell engagers) are not described in the fetched filings.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0001496323"},{"label":"Concentra acquisition agreement (8-K exhibit 99.1, July 2025)","url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525153576/d82329dex991.htm"},{"label":"Completion of merger (8-K, August 2025)","url":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525180763/d82965d8k.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0001496323"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["bispecific-antibody","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Former Nasdaq ticker IGMS. The company had pivoted from oncology to autoimmune disease before winding down; that pivot is not documented in the fetched sources. The July 2025 release is datelined Mountainview while the August 8-K lists a San Mateo address."],"hq":"Mountain View, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1496323/000119312525153576/d82329dex991.htm","note":"$1.247 in cash per share plus a contingent value right; agreement 1 July 2025, merger completed 14 August 2025"}]},"route":"/companies/igm-biosciences/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}]}}